Cargando…
A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma
Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however, high-grade toxicities can occur, particularly during combination therapy. Herein, we report a patient with advanced...
Autores principales: | Gourari, Karim, Catherine, Julien, Garaud, Soizic, Kerger, Joseph, Lepida, Antonia, Georgala, Aspasia, Lebrun, Fabienne, Gomez Galdon, Maria, Gil, Thierry, Willard-Gallo, Karen, Langouo Fontsa, Mireille |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871391/ https://www.ncbi.nlm.nih.gov/pubmed/35204627 http://dx.doi.org/10.3390/diagnostics12020539 |
Ejemplares similares
-
Infliximab-Induced Vanishing Bile Duct Syndrome
por: Eiswerth, Michael J, et al.
Publicado: (2022) -
Vanishing Bile Duct Syndrome Associated With Estrogen
por: Benfield, John, et al.
Publicado: (2022) -
FRI088 Vanishing Bile Duct Syndrome?
por: Malvar, Cyerwin Monique T, et al.
Publicado: (2023) -
Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment
por: Boisson, Anaïs, et al.
Publicado: (2021) -
Vanishing Bile Duct Syndrome in the Presence of Hodgkin Lymphoma
por: Gaudel, Pramod, et al.
Publicado: (2022)